- Home
- WF vs MRNA Comparison
WF vs MRNA Comparison
Compare WF & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | MRNA |
|---|---|---|
| Founded | 1899 | 2010 |
| Country | South Korea | United States |
| Employees | N/A | 5800 |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 11.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WF | MRNA |
|---|---|---|
| Price | $56.30 | $29.47 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $33.25 |
| AVG Volume (30 Days) | 57.4K | ★ 9.8M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | ★ 20.51 | N/A |
| EPS | ★ 2.97 | N/A |
| Revenue | ★ $8,054,512,650.00 | $2,232,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.26 | $0.77 |
| P/E Ratio | $6.26 | ★ N/A |
| Revenue Growth | ★ 23.56 | N/A |
| 52 Week Low | $29.44 | $22.28 |
| 52 Week High | $59.88 | $48.92 |
Technical Indicators
Market Signals| Indicator | WF | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 65.99 |
| Support Level | $56.91 | $26.90 |
| Resistance Level | $57.75 | $26.00 |
| Average True Range (ATR) | 0.97 | 1.14 |
| MACD | 0.03 | 0.59 |
| Stochastic Oscillator | 49.61 | 85.99 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.